Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Apellis Pharmaceuticals, Inc. (NASDAQ: APLS).

Full DD Report for APLS

You must become a subscriber to view this report.


Recent News from (NASDAQ: APLS)

Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH
Treatment with APL-2 in eculizumab-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) resulted in broad control of hemolysis and normalization of mean hemoglobin to 12.2 g/dL by day 85, an increase of 4.2 g/dL from baseline Previously transfusion-dependent patients di...
Source: GlobeNewswire
Date: December, 02 2018 12:01
Apellis Pharmaceuticals Expands Leadership Team, Appoints Adam Townsend as Chief Commercial Officer
CRESTWOOD, Ky. and WALTHAM, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announ...
Source: GlobeNewswire
Date: November, 20 2018 07:00
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
CRESTWOOD, Ky. and WALTHAM Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today an...
Source: GlobeNewswire
Date: November, 07 2018 16:30
Apellis Pharmaceuticals Announces Poster Presentations at the American Society of Hematology Annual Meeting
CRESTWOOD, Ky. and WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals  Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, an...
Source: GlobeNewswire
Date: November, 01 2018 10:50

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0817.7517.1717.9816.90253,018
2018-05-1723.7024.5024.57523.52286,006

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0718,43441,92043.9742Short
2018-12-0633,906113,08929.9817Cover
2018-12-04256,689532,77248.1799Short
2018-12-0338,334157,43724.3488Cover
2018-11-309,97633,73729.5699Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on APLS.


About Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)

Logo for Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: APLS)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: April, 30 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 25 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 25 2018
      Prospectus filed under Rule 424(b)(4)
      Filing Type: 424B4Filing Source: edgar
      Filing Date: April, 19 2018
      Registration of up to an additional 20% of securities for any offering registered on an S-1
      Filing Type: S-1MEFFiling Source: edgar
      Filing Date: April, 18 2018
      Notice from the SEC of registration effectiveness
      Filing Type: EFFECTFiling Source: edgar
      Filing Date: April, 18 2018
      General form for registration of securities under the Securities Act of 1933
      Filing Type: S-1Filing Source: edgar
      Filing Date: April, 16 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 02 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 19 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: APLS)

      Daily Technical Chart for (NASDAQ: APLS)


      Stay tuned for daily updates and more on (NASDAQ: APLS)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: APLS)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in APLS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of APLS and does not buy, sell, or trade any shares of APLS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/